Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pavia – page 203

2 866 clinical trials in Pavia, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pavia at a glance
2 866
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

2 866 trials in Pavia

Open in trial search

Study on Retreatment with Encorafenib and Cetuximab for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cervix carcinoma

Not recruiting

Study on the Effectiveness of HPV 9-Valent Vaccine in Women Undergoing LEEP for High-Grade Cervical Lesions or Early Cervical Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Water For Injection
  • Sponsor:Azienda Unita Sanitaria Locale Toscana Nord Ovest

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Riliprubart for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganciclovir Sodium
  • Sponsor:Viracta Therapeutics Inc.

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Brain stem glioma

Not recruiting

Study on Radiotherapy with Nimotuzumab and Vinorelbine for Newly Diagnosed Childhood and Adolescent Diffuse Intrinsic Pontine Glioma (DIPG) Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nimotuzumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Pavia

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiac conditions, including research on TTR amyloidosis and specialized therapies for pulmonary hypertension.

  • Heart Disease Prevention
  • Pulmonary Arterial Hypertension
  • Ventricular Tachycardia

Clinical trials evaluating new therapeutic approaches for cardiovascular complications and heart rhythm disorders.

02 Neurological Disorders

Studies investigating treatments for acute ischemic stroke and progressive neurological conditions, with particular focus on improving patient outcomes and functional recovery.

  • Stroke Treatment
  • Parkinson's Disease
  • Dravet Syndrome

Advanced research exploring innovative therapeutic approaches for various neurological conditions.

03 Autoimmune and Inflammatory Conditions

Research targeting chronic spontaneous urticaria, various forms of arthritis, and systemic autoimmune conditions affecting multiple organ systems.

  • Psoriatic Arthritis
  • Systemic Sclerosis
  • Immune System Disorders

Evaluation of novel therapies aimed at managing inflammatory responses and improving quality of life.

04 Respiratory Medicine

Comprehensive studies on chronic obstructive pulmonary disease and bronchiectasis, focusing on exacerbation prevention and symptom management.

  • COPD Treatment
  • Non-Cystic Fibrosis Bronchiectasis
  • Lung Fibrosis

Investigation of innovative therapeutic approaches for chronic respiratory conditions.

05 Hematology and Oncology

Advanced research in multiple myeloma and related blood disorders, including chronic myeloid leukemia and myelodysplastic syndromes.

  • Blood Cancers
  • Amyloidosis
  • Transfusion-Dependent Anemia

Development of targeted therapies for various hematological conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.